Friday 5 February 2021, 4:30 PM – 5:30 PM CET
As part of the EFCCA Patient Talks series, we organised our latest EFCCA Patient Talk which took place on Friday 5 February 2021 from 4.30 to 5.30 pm (CET) at our EFCCA Facebook
The worldwide rollout of coronavirus vaccination has begun and so did interrogations of our community around this theme. “Are the coronavirus vaccines safe? How will the vaccines impact Crohn’s disease and Ulcerative Colitis? When will the vaccines be available for IBD patients?” are just some of the questions addressed to EFCCA members.
EFCCA is aiming to respond them in collaboration with representatives from the United European Gastroenterology (UEG) and the European Association of Hospital Pharmacists (EAHP) at our webinar that took place on 5 February at 4.30 to 5.30 pm (CET).
Prof. Axel Dignass, President of the United European Gastroenterology (UEG) will discuss the potential concerns and implications around the COVID-19 vaccination with relation to inflammatory bowel diseases.
Dr. András Süle, President – Elect at European Association of Hospital Pharmacists (EAHP) will talk about COVID-19 vaccine programmes and the challenges that their implementation and administration will follow when more vaccine will become available. Read the EAHP Opinion on COVID-19 Vaccine Programmes and their Implementation here
Programme:
4.30 - 4.35 pm (CET)
Welcome and introduction to the webinar: Ciara Drohan, EFCCA Vice President (tbc)
4.35 - 4.50 pm (CET)
Prof. Axel Dignass, President, United European Gastroenterology (UEG), Concerns and implications around the COVID-19 vaccination for the IBD community, see presentation.pdf
4.50 - 5.05 pm (CET)
Dr. András Süle, President – Elect, European Association of Hospital Pharmacists (EAHP), Challenges to the Covid-19 Vaccine Programmes and their implementation.pdf
5.05 - 5.15 pm (CET)
Maria Stella De Rocchis, Outcomes of the EFCCA survey on COVID-19 vaccination protocols.pdf
5.15 - 5.30 pm (CET)
Questions and Answers